Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website https://www.gastrores.org

Original Article

Volume 13, Number 4, August 2020, pages 138-145

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital

**Table 1.** Baseline Patient Characteristics
Serial number	Age	Sex	Smoker	PPI/HRA	IC	CCI
^aChemotherapy for breast cancer, non-Hodgkin lymphoma. ^bImmunotherapy for inflammatory bowel disease. ^cChemotherapy for breast cancer. ^dChemotherapy for lung cancer. PPI: proton pump inhibitor; HRA: histamine receptor antagonist; IC: immunocompromised; CCI: Charlson comorbidity index.
1	88	F	Yes	PPI	No	7
2	84	M	Yes	HRA	No	11
3	60	F	Yes	PPI	No	11
4	61	M	No	None	No	2
5	51	F	No	None	No	1
6	79	F	Yes	PPI	No	5
7	60	F	No	None	No	2
8	68	F	No	PPI	Yes^a	5
9	37	F	Yes	PPI	Yes^b	0
10	63	F	No	None	Yes^b	2
11	46	F	Yes	HRA	Yes^c	2
12	38	M	Yes	PPI	Yes^b	0
13	73	M	Yes	PPI	Yes^d	15
14	76	F	Yes	PPI	No	5
15	40	M	Yes	PPI	No	0
16	86	M	Yes	PPI	No	9
17	39	F	Yes	PPI	No	1
18	68	F	No	PPI	No	4
19	75	M	Yes	None	No	4
20	56	F	Yes	PPI	No	5

Table 1. Baseline Patient Characteristics

Serial number

Age

Sex

Smoker

PPI/HRA

CCI

^aChemotherapy for breast cancer, non-Hodgkin lymphoma. ^bImmunotherapy for inflammatory bowel disease. ^cChemotherapy for breast cancer. ^dChemotherapy for lung cancer. PPI: proton pump inhibitor; HRA: histamine receptor antagonist; IC: immunocompromised; CCI: Charlson comorbidity index.

Yes

PPI

Yes

HRA

Yes

PPI

None

Yes

PPI

None

PPI

Yes^a

Yes

PPI

Yes^b

None

Yes^b

Yes

HRA

Yes^c

Yes

PPI

Yes^b

Yes

PPI

Yes^d

Yes

PPI

Yes

PPI

Yes

PPI

Yes

PPI

Yes

None

Yes

PPI

**Table 2.** Characteristics of Patients With FMT Recurrence and Subsequent Treatment
Serial number	Antibiotic use before initial CDI	Number of recurrences before FMT	Antibiotics used to treat initial CDI	Antibiotic use before recurrence	Time of recurrence after FMT	Treatment for recurrence after FMT	Death
FMT: fecal microbiota transplantation; CDI: Clostridium difficile infection; M: metronidazole; V: vancomycin.
1	Yes	6	M	Yes	18 months	V	No
2	Yes	5	M	-	None	-	No
3	Yes	3	M + V	-	None	-	No
4	Yes	4	M + V	-	None	-	No
5	Yes	3	M + V	-	None	-	No
6	Yes	3	M	-	None	-	No
7	No	3	M	No	5 months	FMT	No
8	Yes	7	M + V	No	2 weeks	FMT	No
9	Yes	4	M	-	None	-	No
10	No	3	V	No	10 days	FMT	No
11	No	3	M	-	None	-	No
12	No	4	V	No	10 months	V	No
13	No	4	M	-	None	-	No
14	Yes	4	M	-	None	-	No
15	Yes	6	M	-	None	-	No
16	Yes	4	M	-	None	-	Yes
17	No	4	M	No	8 months	M	No
18	No	4	M + V	-	None	-	No
19	Yes	2	M + V	-	None	-	No
20	No	10	V	-	None	-	Yes

Table 2. Characteristics of Patients With FMT Recurrence and Subsequent Treatment

Serial number

Antibiotic use before initial CDI

Number of recurrences before FMT

Antibiotics used to treat initial CDI

Antibiotic use before recurrence

Time of recurrence after FMT

Treatment for recurrence after FMT

Death

FMT: fecal microbiota transplantation; CDI: Clostridium difficile infection; M: metronidazole; V: vancomycin.

Yes

18 months

Yes

None

Yes

M + V

None

Yes

M + V

None

Yes

M + V

None

Yes

None

5 months

FMT

Yes

M + V

2 weeks

FMT

Yes

None

10 days

FMT

None

10 months

None

Yes

None

Yes

None

Yes

None

Yes

8 months

M + V

None

Yes

M + V

None

Yes

**Table 3.** Characteristics of Patients With and Without FMT Failure
Variable	Early FMT failure (n = 2)	Late FMT failure (n = 4)	Total failures (n = 6)	Primary cure (n = 14)
FMT: fecal microbiota transplantation; PPI: proton pump inhibitor; CDI: Clostridium difficile infection; IBD: inflammatory bowel disease; CCI: Charlson comorbidity index; M: metronidazole; V: vancomycin.
Age in years, mean (SD)	65.5 (N/A)	56.3(23.5)	59.3(19)	64(16)
Gender
Female (%)	2 (100)	3 (75)	5 (83)	8(57)
Male (%)	0	1 (25)	1 (17)	6(43)
Mean recurrences before FMT	5	4.25	4.5	4.2
PPI use at the time of initial CDI (%)	1(50)	3 (75)	13 (65)	9 (64.2)
Smoking history (%)	11 (68.7)	3 (75)	14 (70)	11 (78)
Immunosuppressed (%)	2 (100)	1 (25)	3 (50)	3 (21.4)
IBD (%)	1 (50)	1 (25)	2 (33.3)	1 (7)
CCI ≥ 5 (%)	1 (50)	1 (25)	2 (33.3)	6 (43))
Antibiotic use prior to CDI (%)	1 (50)	1 (25)	2 (33.3)	10 (71.4)
Treatment of initial CDI
M (%)	0	3 (75)	3 (50)	8 (57)
V (%)	1 (50)	1 (25)	2 (33.3)	1 (7)
Combined	1 (50)	0	1 (16.7)	5 (36)

Table 3. Characteristics of Patients With and Without FMT Failure

Variable

Early FMT failure (n = 2)

Late FMT failure (n = 4)

Total failures (n = 6)

Primary cure (n = 14)

FMT: fecal microbiota transplantation; PPI: proton pump inhibitor; CDI: Clostridium difficile infection; IBD: inflammatory bowel disease; CCI: Charlson comorbidity index; M: metronidazole; V: vancomycin.

Age in years, mean (SD)

65.5 (N/A)

56.3(23.5)

59.3(19)

64(16)

Gender

Female (%)

2 (100)

3 (75)

5 (83)

8(57)

Male (%)

1 (25)

1 (17)

6(43)

Mean recurrences before FMT

4.25

4.5

4.2

PPI use at the time of initial CDI (%)

1(50)

3 (75)

13 (65)

9 (64.2)

Smoking history (%)

11 (68.7)

3 (75)

14 (70)

11 (78)

Immunosuppressed (%)

2 (100)

1 (25)

3 (50)

3 (21.4)

IBD (%)

1 (50)

1 (25)

2 (33.3)

1 (7)

CCI ≥ 5 (%)

1 (50)

1 (25)

2 (33.3)

6 (43))

Antibiotic use prior to CDI (%)

1 (50)

1 (25)

2 (33.3)

10 (71.4)

Treatment of initial CDI

M (%)

3 (75)

3 (50)

8 (57)

V (%)

1 (50)

1 (25)

2 (33.3)

1 (7)

Combined

1 (50)

1 (16.7)

5 (36)